NEW YORK, May 20-Valentis said today that it has licensed its GeneSwitch gene regulation technology to the German drug developer MediGene.
MediGene will have the rights to use this technology for research purposes, in exchange for an immediate payment and annual maintenance fees.
The companies did not disclose financial details of the agreement.
Valentis' technology allows researchers to regulate the expression of certain genes in transgenic animals and cell cultures, a process useful in gene function identification and target validation.
This is the sixth non-exclusive license that the Burlingame, Calif.-based company has granted to pharmaceutical and biotechnology partners since February 2001.
MediGene, a publicly traded company that focuses on cancer drug development, is based in Martinsreid, with a U.S. subsidiary in San Diego, Calif.
For additional information about the deal, click here.